CCL2 and neoplasm: Together with our previous data, the present results suggest that the blockade of MCP-1/CCR2 pathway by irbesartan reduces the accumulation of fibrocytes into the inflamed colon and might inhibit tumour progression through the reduction of Col I and MMP-9 production.